After a decade of development and multiple clinical setbacks, Sanofi's venglustat has met its primary goal in a Phase 3 trial for Type 3 Gaucher disease, offering new hope for neurological symptoms. The drug, however, failed a separate late-stage study for Fabry disease.
Ardelyx, Inc. (NASDAQ: ARDX) has received significant analyst upgrades, with TD Cowen and Jefferies raising price targets ahead of the company's fourth-quarter results. The optimism centers on the commercial trajectory of its flagship drug, tenapanor, for gastrointestinal and kidney conditions.
The pharmaceutical giant's final major U.S. facility will rise in Pennsylvania's historic Lehigh Valley, aiming to produce its promising triple-hormone drug retatrutide and bolster domestic supply chains for blockbuster obesity treatments.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility dedicated to next-generation weight-loss drugs, signaling a long-term strategic commitment to the obesity market amid intense competition.
Terns Pharmaceuticals has restructured a key licensing deal with China's Hansoh, gaining exclusive worldwide rights for its TERN-701 oncology drug outside Greater China. The strategic move, coupled with a recent analyst price target surge, signals the company's aggressive push into international markets.
Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.
With its blockbuster Humira era in the rearview, AbbVie is betting big on its next-generation immunology drugs and a deep pipeline to drive growth and maintain its crown among Dividend Kings.
Shares of Corcept Therapeutics plunged 16% after a corrected FDA letter disclosed the agency had repeatedly cautioned the company against filing its application for a Cushing's syndrome drug, which was later rejected over efficacy and safety concerns.
LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.
Vera Therapeutics (VERA) is drawing bullish attention from Wall Street, with multiple analysts significantly raising price targets following a key competitor's FDA approval and revised revenue forecasts for its lead drug candidate.
Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.
Bank of America has upgraded Apellis Pharmaceuticals (APLS) to 'Buy,' citing robust early adoption of its drug Empaveli and significant undervaluation of its potential in treating rare kidney diseases, despite a more cautious outlook from Wells Fargo.
A major consumer group has filed a complaint with the Competition and Markets Authority, alleging the pharmacy chains used inflated reference prices to make member discounts appear more substantial than they truly were.
The swearing-in of Rep. Christian Menefee (D-Texas) on Monday tightens the House margin to 218-214, leaving Speaker Mike Johnson with virtually no room for error on key votes, starting with this week's critical government funding bill.
Former President Bill Clinton and former Secretary of State Hillary Clinton have reversed course and agreed to provide testimony to the House Oversight Committee's investigation into Jeffrey Epstein, following the panel's move to hold them in contempt.
Snap Inc. is showing signs of a financial turnaround, powered by its surging Snapchat+ subscription service and strategic AI investments. As daily active users approach half a billion, analysts are reassessing the social media pioneer's long-term potential.
A Democrat's symbolic victory in a Texas Senate district, which Trump won by 17 points, sends shockwaves through Republican strategy to retain the U.S. House, highlighting potential cracks in GOP support among suburban and Hispanic voters.
Gökçe Güven, CEO of rewards startup Kalder and a 2023 Forbes 30 Under 30 honoree, is charged with securities fraud, wire fraud, and visa fraud. Prosecutors allege she used falsified data to raise millions from investors.
Bill and Hillary Clinton have agreed to appear before the House Oversight Committee as part of its investigation into the Jeffrey Epstein case, a spokesperson confirmed, signaling a major development in the long-running inquiry.
While the fried chicken segment continues to dominate fast-food traffic, Buffalo-based Hen House Nashville Hot Chicken has filed for bankruptcy protection, highlighting the uneven fortunes within the popular sector.
